A Phase 2 interventional study of Rabeprazole sodium, 5 mg Tablets and Rabeprazole sodium, 10 mg Tablets in Healthy, sponsored by Eisai Co., Ltd.. Completed at 1 site in Japan. Open to male participants aged 20 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2012-11-30.
Sponsored by Eisai Co., Ltd. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to compare the pharmacodynamics/pharmacokinetics of 5 mg, 10 mg, 20 mg and 40 mg of Rabeprazole sodium (E3810) when administered repeatedly once daily for 5 days to healthy adult male Japanese participants. This was a single-center, open-label, randomized, four-treatment, four-way crossover study.
Eisai Co., Ltd. is the lead sponsor of 152 studies on the registry; 5 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Rabeprazole sodium, 5 mg Tablets
Drug: Rabeprazole sodium, 10 mg Tablets
Drug: Rabeprazole sodium, 20 mg Tablets
Drug: Rabeprazole sodium, 40 mg Tablets (two 20 mg Tablets)
Rabeprazole sodium Tablets, 5 mg administered for 5 days. Day 1 and Day 5: participants received a single dose with 200 mL of water in the morning while fasting for 10 hours or longer. Day 2 to Day 4: participants received a single dose with 200 mL of water \>= 2 hours after the completion of breakfast.
Also known as: E3810, E3810-J081-040
Rabeprazole sodium Tablets, 10 mg administered for 5 days. Day 1 and Day 5: participants received a single dose with 200 mL of water in the morning while fasting for 10 hours or longer. Day 2 to Day 4: participants received a single dose with 200 mL of water \>= 2 hours after the completion of breakfast.
Also known as: E3810, E3810-J081-040
Rabeprazole sodium Tablets, 20 mg administered for 5 days. Day 1 and Day 5: participants received a single dose with 200 mL of water in the morning while fasting for 10 hours or longer. Day 2 to Day 4: participants received a single dose with 200 mL of water \>= 2 hours after the completion of breakfast.
Also known as: E3810, E3810-J081-040
Rabeprazole sodium Tablets, 40 mg (two 20 mg Tablets) administered for 5 days. Day 1 and Day 5: participants received a single dose with 200 mL of water in the morning while fasting for 10 hours or longer. Day 2 to Day 4: participants received a single dose with 200 mL of water, \>=2 hours after the completion of breakfast.
Also known as: E3810, E3810-J081-040
Percentage Duration With An Intragastric pH >= 4 During The Entire 24 Hours Of Day 5 Administration
The 24-hour intragastric pH monitoring was performed on Day 5 of administration in each study period (Period I-IV). Data was displayed based on the participant's CYP2C19 genotype: CYP2C19-EM are extensive metabolizers who have normal metabolizing capacity. CYP2C19-PM are poor metabolizers with a metabolizing capacity deficiency or remarkably decreased metabolizing capacity.
Time frame: Day 5 of administration during Period I-IV
Pharmacokinetic Parameter: Maximal Drug Concentration (Cmax)
Pharmacokinetic parameter: maximal drug concentration (Cmax) measured in nanograms per milliliter (ng/mL) was calculated on Day 1 and Day 5 of administration during each Period (I-IV). Data was displayed based on the participant's CYP2C19 genotype: CYP2C19-EM are extensive metabolizers who have normal metabolizing capacity. CYP2C19-PM are poor metabolizers with a metabolizing capacity deficiency or remarkably decreased metabolizing capacity.
Time frame: Day 1 and Day 5 of administration during Period I-IV
Pharmacokinetic Parameter: Area Under the Plasma Concentration-Time Curve From Time 0 to Time t (AUC[0-t])
Pharmacokinetic parameter: Area under the plasma concentration-time curve from time 0 (administration of the drug) to time t (the last quantifiable concentration time point). AUC measured in nanogram hours per milliliter (ng\*h/mL) was calculated on Day 1 and Day 5 of administration during each Period (I-IV). Data was displayed based on the participant's CYP2C19 genotype: CYP2C19-EM are extensive metabolizers who have normal metabolizing capacity. CYP2C19-PM are poor metabolizers with a metabolizing capacity deficiency or remarkably decreased metabolizing capacity.
Time frame: Day 1 and Day 5 of administration during Period I-IV (0, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 8, 10, 12, 24 hours post-dose)
This study was recruited at 1 center in Japan during the period of 14-Sep-2010 to 2-Dec-2010.
| Milestone | Group A: Rapeprazole 5 mg, Then 10 mg, Then 20 mg, Then 40 mg | Group B: Rapeprazole 10 mg, Then 20 mg, Then 40 mg, Then 5 mg | Group C: Rapeprazole 20 mg, Then 40 mg, Then 5 mg, Then 10 mg | Group D: Rapeprazole 40 mg, Then 5 mg, Then 10 mg, Then 20 mg |
|---|---|---|---|---|
| Started | 6 | 6 | 6 | 6 |
| Completed | 6 | 6 | 6 | 6 |
| Not completed | 0 | 0 | 0 | 0 |
The 24-hour intragastric pH monitoring was performed on Day 5 of administration in each study period (Period I-IV). Data was displayed based on the participant's CYP2C19 genotype: CYP2C19-EM are extensive metabolizers who have normal metabolizing capacity. CYP2C19-PM are poor metabolizers with a metabolizing capacity deficiency or remarkably decreased metabolizing capacity.
| Percentage of Time in a 24 Hour Period | Rabeprazole Sodium 5 mg Tablet | Rabeprazole Sodium 10 mg Tablet | Rabeprazole Sodium 20 mg Tablet | Rabeprazole Sodium 40 mg Tablet |
|---|---|---|---|---|
| CYP2C19 Extensive Metabolizers 'EM' (n=16) | 45.63 ± 19.17 | 57.81 ± 12.93 | 61.36 ± 9.72 | 71.52 ± 12.20 |
| CYP2C19 Poor Metabolizers 'PM' (n=8) | 62.51 ± 14.79 | 71.83 ± 14.64 | 75.74 ± 20.62 | 83.08 ± 11.13 |
Pharmacokinetic parameter: maximal drug concentration (Cmax) measured in nanograms per milliliter (ng/mL) was calculated on Day 1 and Day 5 of administration during each Period (I-IV). Data was displayed based on the participant's CYP2C19 genotype: CYP2C19-EM are extensive metabolizers who have normal metabolizing capacity. CYP2C19-PM are poor metabolizers with a metabolizing capacity deficiency or remarkably decreased metabolizing capacity.
| ng/mL | Rabeprazole Sodium 5 mg Tablet | Rabeprazole Sodium 10 mg Tablet | Rabeprazole Sodium 20 mg Tablet | Rabeprazole Sodium 40 mg Tablet |
|---|---|---|---|---|
| Day 1: CYP2C19 Extensive Metabolizers 'EM' (n=16) | 137.7 ± 55.7 | 253.6 ± 120.2 | 520.0 ± 267.7 | 1007.6 ± 513.1 |
| Day 5: CYP2C19 Extensive Metabolizers 'EM' (n=16) | 146.0 ± 56.4 | 382.8 ± 82.9 | 654.1 ± 348.4 | 1018.5 ± 516.9 |
| Day 1: CYP2C19 Poor Metabolizers 'PM' (n=8) | 185.1 ± 79.0 | 434.7 ± 98.5 | 891.9 ± 210.8 | 1574.2 ± 596.6 |
| Day 5: CYP2C19 Poor Metabolizers 'PM' (n=8) | 251.9 ± 55.1 | 508.5 ± 63.8 | 821.9 ± 231.7 | 1986.5 ± 439.1 |
Pharmacokinetic parameter: Area under the plasma concentration-time curve from time 0 (administration of the drug) to time t (the last quantifiable concentration time point). AUC measured in nanogram hours per milliliter (ng\*h/mL) was calculated on Day 1 and Day 5 of administration during each Period (I-IV). Data was displayed based on the participant's CYP2C19 genotype: CYP2C19-EM are extensive metabolizers who have normal metabolizing capacity. CYP2C19-PM are poor metabolizers with a metabolizing capacity deficiency or remarkably decreased metabolizing capacity.
| ng*h/mL | Rabeprazole Sodium 5 mg Tablet | Rabeprazole Sodium 10 mg Tablet | Rabeprazole Sodium 20 mg Tablet | Rabeprazole Sodium 40 mg Tablet |
|---|---|---|---|---|
| Day 1: CYP2C19 Extensive Metabolizers 'EM' (n=16) | 215.5 ± 88.4 | 429.7 ± 209.4 | 866.9 ± 385.6 | 1807.2 ± 949.2 |
| Day 5: CYP2C19 Extensive Metabolizers 'EM' (n=16) | 235.7 ± 97.1 | 539.1 ± 199.6 | 993.7 ± 476.9 | 1929.6 ± 884.1 |
| Day 1: CYP2C19 Poor Metabolizers 'PM' (n=8) | 455.0 ± 137.7 | 1029.6 ± 293.9 | 2112.9 ± 628.8 | 4002.3 ± 1216.0 |
| Day 5: CYP2C19 Poor Metabolizers 'PM' (n=8) | 584.6 ± 137.1 | 1230.4 ± 200.0 | 2330.6 ± 662.9 | 4627.9 ± 1296.0 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Rabeprazole Sodium 5 mg Tablet | — | 0/24 (0%) | 0/24 (0%) |
| Rabeprazole Sodium 10 mg Tablet | — | 0/24 (0%) | 0/24 (0%) |
| Rabeprazole Sodium 20 mg Tablet | — | 0/24 (0%) | 0/24 (0%) |
| Rabeprazole Sodium 40 mg Tablet | — | 0/24 (0%) | 0/24 (0%) |
| Age Continuous(years) | Entire Study Population: Group A, Group B, Group C, Group D |
|---|---|
| Mean | 27.7 ± 4.5 |
| Sex: Female, Male(Participants) | Entire Study Population: Group A, Group B, Group C, Group D |
|---|---|
| Female | 0 |
| Male | 24 |
| Baseline Percentage Duration With An Intragastric pH >= 4 During The Entire 24 Hours on Day 1(Percentage of Time in a 24 Hour Period) | Entire Study Population: Group A, Group B, Group C, Group D |
|---|---|
| CYP2C19 Extensive Metabolizers 'EM' | 12.57 ± 7.55 |
| CYP2C19 Poor Metabolizers 'PM' | 9.91 ± 8.50 |
The record gives a start of Sep 2010, a primary completion of Dec 2010 and a completion of Dec 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2012, 1 year 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rabeprazole